Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triple Negative Breast Cancer Trial: Carboplatin vs Docetaxel in Metastatic or Locally Advanced Disease
2006-004470-26Phase 4Unknown
- Sponsor
- The Institute of Cancer Research
- Start
- Feb 2008
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in triple-negative breast cancer (TNBC) comparing Carboplatin arm with Docetaxel arm (2 arms). Primary endpoint: Objective tumor response rate (CR + PR). Status: unknown.
02
Drugs
carboplatindocetaxel
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on 2006-004470-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004470-26.